Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX) reported that the independent Data Safety and Monitoring Committee has issued a positive recommendation to advance its Phase 1 ‘HEAT’ trial of radiotherapeutic candidate 177Lu-RAD202 (RAD202) in HER2-positive advanced solid tumors to Cohort 4 at a 180mCi dose level.According to the company, the DSMC’s review supports the safety profile observed so far and enables continued evaluation at higher doses at clinical centers across Australia. RAD202 is a proprietary single-domain monoclonal antibody targeting HER2; in a previous diagnostic study in ten HER2-positive breast cancer patients it showed clinical proof-of-concept with positive safety and biodistribution.

Radiopharm Theranostics (ASX:RAD) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Radiopharm Theranostics’s share pr

Radiopharm Theranostics (ASX:RAD) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Radiopharm Theranostics’s share pr

177Lu-RAD202 demonstrated encouraging tumor uptake and a favorable safety profile in the lowest dose cohort Data Safety and Monitoring Committee Recently Approved Advancing 177Lu-RAD202 to Next Highes...

Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to progress Phase 1 to the next dose level of 130mCi in patients with HER2+ advanced solid tumorsSYDNEY, April 08, 202...

Phase 1 study to progress to the next dose level of 75mCi in patients with HER2+ advanced solid tumors, instead of the protocol-planned dose of 40mCiSYDNEY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Radiophar...

Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in individuals with advanced HER2-positive solid tumors Previo...

Reported Wednesday, Apr 8 - 7:18am EDT (TheFly subscription required to read more.)

Reported Monday, Mar 17 - 8:58am EDT (TheFly subscription required to read more.)

Radiopharm Theranostics (NASDAQ: RADX) received a positive DSMC recommendation to advance 177Lu-RAD202 to 130mCi (Cohort 3) in the Phase 1 HEAT trial for HER2+ advanced solid tumors.The study is ongoing at Australian sites, the prior dose level was 75mCi (announced 1 Oct 2025), and management says dose escalation remains on track to complete by end of 2026.

Radiopharm Theranostics (NASDAQ: RADX), a clinical-stage biopharmaceutical company, reported significant progress across its radiopharmaceutical pipeline for FY2025. Key developments include FDA Fast Track Designation for RAD101 for brain metastases treatment differentiation, positive DSMC recommendation for RAD204 dose escalation to 60mCi, and advancement in the Phase 1 'HEAT' trial of RAD202 for HER2-positive tumors.The company maintains a strong financial position with cash balance of $29.12 million, up from $18.58 million year-over-year, providing runway through mid-2026. Notable achievements include IND clearance for RV-01, strategic supply agreements with ITM and Cyclotek for radioisotopes, and progression across multiple clinical trials with data readouts expected in H2 2025.

Phase 1 1 First-In-Human study designed to assess safety , tolerability , right dose for Phase 2 and early signs of efficacy of 177Lu-RAD20 2 in individuals with advanced HER2-positive solid tumors Previous clinical proof-of concept data 2 for targeting HER-2 demonstrated the safety and

New clinical data reveals RAD202's superior tumor targeting and survival benefits in HER2-positive cancers. Phase I trial now recruiting for advanced solid tumors.